Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 9/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14723344 | 0.87 | GAA (0.55) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL14723167 | 0.87 | GAA (0.68) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL15209528 | 0.84 | GAA (0.45) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL14722627 | 0.84 | GAA (0.45) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL1847788 | 0.84 | GAA (0.52) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL14723224 | 0.81 | HPGD (0.53) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL14723227 | 0.81 | GAA (0.48) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL1844662 | 0.77 | HSD17B10 (0.42) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL1844583 | 0.76 | FGFR1 (0.44) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL15208541 | 0.76 | GAA (0.46) | GAAHSD17B10HPGDALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2748159-A1 | SERINE/THREONINE PAK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | GAA 3564/4885HSD17B10 3921/4885HPGD 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.